BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

Key Points

• BioMarin issued FY 2026 guidance of $4.90–$5.10 in earnings per share, above the $4.80 consensus estimate, while revenue guidance of approximately $3.9 billion matched expectations.
• The company’s latest quarter exceeded forecasts, reporting EPS of $1.20 versus the $0.94 consensus and revenue of $989.71 million versus expectations of $932.03 million.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $87.09, while institutional investors and hedge funds own 98.71% of the stock.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 4.900-5.100 for the period, compared to the consensus EPS estimate of 4.800. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analyst Ratings Changes

BMRN has been the topic of several recent research reports. HC Wainwright restated a "neutral" rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, July 14th. Morgan Stanley decreased their price target on BioMarin Pharmaceutical from $120.00 to $119.00 and set an "overweight" rating for the company in a report on Tuesday, May 5th. Sanford C. Bernstein dropped their price objective on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 5th. Citigroup raised their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research note on Thursday, July 16th. Finally, The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They issued a "neutral" rating and a $69.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $87.09.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock traded up $1.55 during midday trading on Thursday, reaching $61.46. 3,446,826 shares of the company traded hands, compared to its average volume of 2,044,165. The firm's 50 day simple moving average is $57.89 and its two-hundred day simple moving average is $56.96. The firm has a market cap of $11.88 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $66.28.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.26. The business had revenue of $989.71 million for the quarter, compared to analysts' expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts expect that BioMarin Pharmaceutical will post 4.22 EPS for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after buying an additional 179 shares during the period. Parallel Advisors LLC raised its holdings in BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 295 shares during the period. Algert Global LLC lifted its position in BioMarin Pharmaceutical by 0.8% during the 3rd quarter. Algert Global LLC now owns 40,210 shares of the biotechnology company's stock worth $2,178,000 after acquiring an additional 336 shares during the last quarter. NewEdge Advisors LLC lifted its position in BioMarin Pharmaceutical by 11.5% during the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock worth $266,000 after acquiring an additional 388 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in BioMarin Pharmaceutical by 0.9% during the third quarter. Public Employees Retirement System of Ohio now owns 60,427 shares of the biotechnology company's stock valued at $3,273,000 after acquiring an additional 532 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source